Grand Pharmaceutical's (HKG:0512) phase 2 clinical trial of its STC3141 drug for sepsis in China achieved clinical endpoints, according to a Tuesday filing with the Hong Kong bourse.
The results confirmed the effectiveness and safety of STC3141 in the treatment of sepsis, showing the drug achieved a lower sequential organ failure assessment score compared with the baseline.
The first treatment program centered on rebuilding immune homeostasis worldwide, the filing said.
The trial, conducted by Grand Pharma's Australian subsidiary Grand Medical, enrolled 180 patients, according to the filing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。